Co-expression of CCR7 and H3K9me3 identifies aggressive B-cell lymphoma with bone marrow infiltration and poor prognosis.
Two protein markers on lymphoma cells together identify aggressive tumors with spread to bone marrow and poor survival, offering clinicians a new risk assessment tool.
Dual IHC for CCR7 and H3K9me3 in B-cell lymphoma tissue identifies a high-risk subgroup with bone marrow infiltration and significantly inferior progression-free survival, validated by mechanistic co-immunoprecipitation assays. The dual biomarker could serve as a complementary risk stratification tool alongside existing markers like IPI for aggressive lymphomas.
What the study was
- Study design
- Retrospective cohort (IHC + mechanistic assays)
- Population
- B-cell lymphoma patients (tissue biopsy cohort)
- Category
- Diagnostics
- Maturity
- Exploratory
- Journal
- European Cytokine Network
Why it surfaced
Novel dual biomarker (CCR7+H3K9me3) with mechanistic support; Eur Cytokine Netw is not a top-tier hematology journal; sample size not reported in abstract; single-center IHC data.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.